Home › Research › Health systems and care delivery
"Drugs to avoid" to improve quality use of medicines: how is Australia faring?
Vitry Agnes, Mintzes Barbara. Journal of pharmaceutical policy and practice, 2021-07-15
Topic: Risk, prevention and care in population studies
Plain-language summary
Each year, the French independent bulletin Prescrire publishes a list of medicines, "Drugs to avoid", that should not be used in clinical practice as their risk-to-benefit ratio is unfavourable. This study assessed the market approval, reimbursement and use of these medicines in Australia. The approval status of the medicines included in 2019 Prescrire "Drugs to avoid" list was assessed by searching the Australian Register of Therapeutic Goods website. Funding status was assessed on the Pharmaceutical Benefits Scheme (PBS) website, the Australian public insurance system. Use levels were determined by examining governmental reports on prescribing rates including the Australian Statistics on Medicines (ASM) reports, drug use reports released by the Drug Utilisation Sub Committee (DUSC) and PBS statistics. Of the 93 medicines included in the Prescrire 2019 "Drug to avoid" list included, 57 (61%) were approved in Australia in 2019 including 9 (16%) that were sold as over-the-counter medicines, 35 (38%) were listed on the PBS, 22 (24%) were registered but not listed on the PBS. Although most of these medicines were used infrequently, 16 (46%) had substantial use despite serious safety concerns. Dipeptidyl peptidase-4 (DPP-4) inhibitors were used by 22% of patients receiving a treatment for diabetes in 2016. More than 50,000 patients received an anti-dementia medicine in 2014, a 19% increase since 2009. Denosumab became the 8th medicine, in terms of total sales, funded by the Australian Government in 2017-2018. Prescrire's assessments provide a reliable external benchmark to assess the current use of medicines in Australia. Sixteen "drugs to avoid", judged to be more harmful than beneficial based on systematic, independent evidence reviews, are in substantial use in Australia. These results raise serious concerns about the awareness of Australian clinicians of medicine safety and efficacy. Medicines safety has become an Australian National Health Priority. Regulatory and reimbursement agencies should review the marketing and funding status of medicines which have not been shown to provide an efficacy and safety at least similar to alternative therapeutic options.
What this study adds
Evidence grade: Low
The record lists 50,000 participants. This study assessed how many medicines on a 'Drugs to avoid' list were approved, funded, and used in Australia, noting that more than 50,000 patients received an anti-dementia medicine in 2014. It is about medicine regulation and use, not about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Agnes, V., & Barbara, M. (2021). "Drugs to avoid" to improve quality use of medicines: how is Australia faring? Journal of pharmaceutical policy and practice. https://doi.org/10.1186/s40545-021-00346-3
Vancouver
Agnes V, Barbara M. "Drugs to avoid" to improve quality use of medicines: how is Australia faring? Journal of pharmaceutical policy and practice. 2021. doi:10.1186/s40545-021-00346-3. PMID: 34256874.
BibTeX
@article{agnes2021-34256874,
author = {Agnes, Vitry and Barbara, Mintzes},
title = {{"Drugs to avoid" to improve quality use of medicines: how is Australia faring?}},
journal = {Journal of pharmaceutical policy and practice},
year = {2021},
doi = {10.1186/s40545-021-00346-3},
pmid = {34256874},
url = {https://doi.org/10.1186/s40545-021-00346-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These results raise serious concerns about the awareness of Australian clinicians of medicine safety and efficacy.
Why it matters
This study assessed how many medicines on a 'Drugs to avoid' list were approved, funded, and used in Australia, noting that more than 50,000 patients received an anti-dementia medicine in 2014. It is about medicine regulation and use, not about treating, curing, or preventing Alzheimer's disease.
Study details
- Participants50,000
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of pharmaceutical policy and practice) |
| Journal's citation record | 0 / 4 | Journal of Pharmaceutical Policy and Practice: journal h-index 50 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 4 / 4 | 50,000 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-17) |
| Citations per year | 0 / 5 | 0.9 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 1 / 6 | Cited 0.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Barbara J. Mintzes: h-index 36 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Sydney: institution h-index 1,464 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34256874) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.